

Strengthening investment proposition for a pre-clinical RNA startup

Background

A preclinical RNA therapeutics company engaged Nuvantta to strengthen its fundraising strategy ahead of a bridge round. While the company had compelling science, its investor materials were fragmented, its claims required benchmarking, and key strategic gaps (clinical positioning, competitive framing, and market clarity) risked slowing investor interest.

Approach

- **Diagnostic Assessment:** Conducted a deep review of the company's data room, investor decks, and scientific claims. Benchmarked positioning against peer RNA companies, market size expectations, and current investor sentiment.
- **Gap Remediation:** Differentiated between communication issues and fundamental strategy gaps. Designed a roadmap to address misalignments, sharpen the investment narrative, and stress-test assumptions.
- **Investor Packaging:** Co-created investor-ready materials including a revised deck, diligence memo, and FAQ library. Prepared leadership for investor Q&A and partner discussions.
- **Ad-hoc Advisory:** Provided inputs on potential collaborations and licensing opportunities relevant to the company's growth trajectory.

Outcome

The review delivered clear recommendations:

- Delivered a structured gap analysis and remediation plan, clarifying what was narrative vs. strategy.
- Produced an integrated investor materials package, strengthening clarity, comparables, and risk-mitigation framing.
- Enabled the company to enter investor discussions with a sharper story, aligned valuation rationale, and a clean diligence record.
- Positioned the client to raise a targeted bridge round, with clear visibility on next financing and partnership options.